PROCEPT BioRobotics’ Aquablation may ease BPH symptoms while preserving function. Read here for a detailed investment ...

Larry Wood, President and CEO, stated total revenue for the third quarter of 2025 was $83.3 million, highlighting strong execution, primarily driven by U.S. capital systems shipped, totaling 58 in the ...

In early October 2026, PROCEPT BioRobotics added veteran cardiac surgeon Dr. Michael Mack to its board as an independent Class II director, while also facing a newly filed securities lawsuit alleging ...

META: $214.48 million (5.3% of AUM) GOOGL: $171.23 million (4.2% of AUM) AMZN: $161.25 million (4.0% of AUM) NVDA: $149.51 million (3.7% of AUM) V: $137.50 million (3.4% of AUM) As of October 21, 2025 ...

Why this governance shift at PROCEPT BioRobotics matters for investors A fresh investor lawsuit and the appointment of cardiac surgeon Dr. Michael Mack to the board put PROCEPT BioRobotics (PRCT) ...

Develops, manufactures, and sells the AquaBeam Robotic System and Aquablation therapy for minimally invasive urologic surgery, primarily targeting benign prostatic hyperplasia (BPH). Generates revenue ...

Full-year 2025 revenue guidance was updated to approximately $323 million, reflecting 44% growth compared to 2024. This includes US system revenue of $95 million, driven by greenfield sales and some ...

View PROCEPT BioRobotics Corp. PRCT stock quote prices, financial information, real-time forecasts, and company news from CNN.

Throughout the last three months, 4 analysts have evaluated PROCEPT BioRobotics (NASDAQ:PRCT), offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments, the ...

REDWOOD CITY, Calif., Nov. 16, 2020 /PRNewswire/ -- PROCEPT® BioRobotics Corporation, a surgical robotics company developing intelligent solutions to transform the field of urology, today announced ...

Fintel reports that on October 7, 2026, Barclays initiated coverage of PROCEPT BioRobotics (BMV:PRCT) with a Overweight recommendation. Separately, consensus target price data for the company as of ...

PROCEPT BioRobotics stock (ISIN US74276L1052) closed at USD 17.16 on Nasdaq on October 2, 2026, gaining 0.82 percent from the prior close. The same-day filing expanded the board from nine to ten ...